Verona Pharma PLC
VRNA
View Detailed Chart
106.910USD
0.000
Market hours （ET）Quotes delayed by 15 min
73.55BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
+Infinity%
1 Month
+0.21%
6 Months
+55.32%
Year to Date
+130.21%
1 Year
+222.89%
View Detailed Chart
TradingKey Stock Score of Verona Pharma PLC
Currency: USD Updated: 2025-10-07Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals.
Verona Pharma PLC's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
106.222
Target Price
-0.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Verona Pharma PLC Highlights
StrengthsRisks
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 8806.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 33.09M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 143.53.
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 78.50M shares, decreasing 5.21% quarter-over-quarter.
Held by Stanley Druckenmiller
Star Investor Stanley Druckenmiller holds 1.00M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.00.
News
Merck to Acquire Verona Pharma for $10 Billion in Bid to Cushion "Patent Cliff" Impact
TradingKey - U.S. pharmaceutical giant Merck (MRK.US) has announced a roughly $10 billion deal to acquire U.K.-based biopharma firm Verona Pharma (VRNA.US), marking a major move into the respiratory disease treatment space.
TradingKeyThu, Jul 10
Merck to Acquire Verona for $10 Billion — A Major Move into Respiratory Care, Shares of VRNA Surge 20%
TradingKey - According to a report by the Financial Times, U.S. pharmaceutical giant Merck (MRK.US) is nearing a deal to acquire Verona Pharma (VRNA.US) for $10 billion, marking Merck’s largest biopharma acquisition since 2023. The acquisition will expand Merck’s presence in the respiratory disease
TradingKeyWed, Jul 9
Financial Indicators
EPS
No Data
Total revenue
No Data
Verona Pharma PLC Info
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Ticker SymbolVRNA
CompanyVerona Pharma PLC
CEODr. David S. Zaccardelli, Pharm.D.
Websitehttps://www.veronapharma.com/
Related Instruments
+0.80%
+1.08%
-14.59%
+0.01%
+0.83%
-0.35%
-1.02%
+0.64%
-15.75%
-0.73%
-0.77%
-0.42%
+0.01%
-0.85%
0.00%
-0.19%
-0.63%
-0.91%
+0.57%
+1.08%Popular Symbols
